Case Report

Volume: 5 | Issue: 1 | Published: Jan 03, 2022 | Pages: 17 - 19 | DOI: 10.24911/JBCGenetics/183-1624791068

Tyrosinemia type I: an unusual case presentation


Authors: Marwa ALMahroos , Mohammed AlMannai


Article Info

Authors

Marwa ALMahroos

Section of Medical Genetics, Children's Hospital, King Fahad Medical City, Riyadh, Saudi Arabia

Mohammed AlMannai

Section of Medical Genetics, Children's Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.

Publication History

Received: June 27, 2021

Revised: October 05, 2021

Accepted: November 14, 2021

Published: January 03, 2022


Abstract


Background: Hereditary tyrosinemia type 1 (HT1) is an autosomal recessive inherited metabolic disorder caused by the fumerylacetoacetate hydrolase enzyme deficiency. It is characterized by liver dysfunction and/ or failure, renal tubular dysfunction. If left untreated it may lead to Fanconi syndrome and neurological crisis (porphyria-like crisis). Nitisinone is the recommended therapy for HT1 in combination with tyrosine and phenylalanine restricted diet. Case Presentation: In this report, we present 3 years and 8-months-old boy who was referred to the Metabolic Clinic after his cousin was diagnosed with HT1. His history was significant for pleural effusion at 8 months of age which contributed to pulmonary tuberculosis. His alpha-fetoprotein was checked (for no apparent reason) at one and a half years of age and was elevated. Upon evaluation at 3 years and 8 months at our facility, his succinylacetone was significantly elevated. Liver function tests and coagulation results were also mildly elevated. Liver ultrasound was routine apart from gallstones. Targeted mutation testing revealed a fumarylacetoacetate hydrolase gene's homozygous pathogenic variant (c.982C>T; p. Gln328*). Conclusion: In conclusion, we presented a patient with an unusual, late presentation of HT1, to highlight the clinical variability in this rare, treatable metabolic disease.

Keywords: Tyrosinemia Type I, Hereditary TyrosinemiaType 1, Nitisinone, FAH, Fumarylacetoacetate Hydrolase